Association between CECs at 2 months and response to therapy
. | . | CECs at 2 mo . | . | . | |
|---|---|---|---|---|---|
. | No. patients . | 11/μL or less, no. (%) . | More than 11/μL, no. (%) . | P . | |
| Global response | |||||
| Complete response | 5 | 1 (2.3) | 4 (10.8) | ||
| Partial response | 13 | 6 (13.6) | 7 (18.9) | ||
| Stable disease | 32 | 16 (36.4) | 16 (43.2) | ||
| Progressive disease | 31 | 21 (47.7) | 10 (27.0) | .03* | |
| CR + PR | 18 | 7 (15.9) | 11 (29.7) | ||
| SD + PD | 63 | 37 (84.1) | 26 (70.3) | .18 | |
| CR + PR + SD | 50 | 23 (52.3) | 27 (73.0) | ||
| PD | 31 | 21 (47.7) | 10 (27.0) | .07 | |
| Clinical benefit | |||||
| SD > 24 wk + PR + CR | 37 | 13 (29.6) | 24 (64.9) | ||
| SD < 24 wk + PD | 44 | 31 (70.4) | 13 (35.1) | .002* | |
| Response at 2 mo | |||||
| Response | 30 | 14 (34.2) | 16 (48.5) | ||
| Stable disease | 22 | 12 (29.3) | 10 (30.3) | ||
| Progression | 22 | 15 (36.6) | 7 (21.2) | .13 | |
. | . | CECs at 2 mo . | . | . | |
|---|---|---|---|---|---|
. | No. patients . | 11/μL or less, no. (%) . | More than 11/μL, no. (%) . | P . | |
| Global response | |||||
| Complete response | 5 | 1 (2.3) | 4 (10.8) | ||
| Partial response | 13 | 6 (13.6) | 7 (18.9) | ||
| Stable disease | 32 | 16 (36.4) | 16 (43.2) | ||
| Progressive disease | 31 | 21 (47.7) | 10 (27.0) | .03* | |
| CR + PR | 18 | 7 (15.9) | 11 (29.7) | ||
| SD + PD | 63 | 37 (84.1) | 26 (70.3) | .18 | |
| CR + PR + SD | 50 | 23 (52.3) | 27 (73.0) | ||
| PD | 31 | 21 (47.7) | 10 (27.0) | .07 | |
| Clinical benefit | |||||
| SD > 24 wk + PR + CR | 37 | 13 (29.6) | 24 (64.9) | ||
| SD < 24 wk + PD | 44 | 31 (70.4) | 13 (35.1) | .002* | |
| Response at 2 mo | |||||
| Response | 30 | 14 (34.2) | 16 (48.5) | ||
| Stable disease | 22 | 12 (29.3) | 10 (30.3) | ||
| Progression | 22 | 15 (36.6) | 7 (21.2) | .13 | |